Abstract:Cancer-related bone erosion occurs frequently in bone metastasis and is associated with severe complications such as chronic bone pain, fractures, and lower survival rates. In recognition of the fact that the darkness hormone melatonin is capable of regulating bone homeostasis, we explored its therapeutic potential in bone metastasis. We found that melatonin directly reduces osteoclast differentiation, bone resorption activity and promotes apoptosis of mature osteoclasts. We also observed that melatonin inhibits RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevents cancer-associated osteoclast differentiation. In lung and prostate bone metastasis models, twice-weekly melatonin treatment markedly reduced tumor volumes and numbers of osteolytic lesions. Melatonin also substantially lowered the numbers of TRAP-positive osteoclasts in tibia bone marrow and RANKL expression in tumor tissue. These findings show promise for melatonin in the treatment of bone metastases.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is cancer - related bone erosion (especially osteolysis in bone metastases), which is associated with severe complications such as chronic bone pain, fractures and lower survival rates. Specifically, the authors explored the potential efficacy of melatonin in the treatment of bone metastases, especially its interference with osteoclast function and its inhibitory effect on the expression of RANKL secreted by tumors, in order to reduce osteolytic lesions in bone metastases. The key points mentioned in the paper include: - Melatonin directly reduces osteoclast differentiation, bone resorption activity, and promotes the apoptosis of mature osteoclasts. - Melatonin inhibits RANKL production in lung cancer and prostate cancer cells by down - regulating the p38 MAPK pathway, thereby preventing cancer - related osteoclast differentiation. - In lung cancer and prostate bone metastasis models, melatonin treatment twice a week significantly reduced the tumor volume and the number of osteolytic lesions. - Melatonin also significantly reduced the number of TRAP - positive osteoclasts in the tibial marrow and the expression of RANKL in tumor tissues. These findings suggest that melatonin may become an effective and safe method for treating bone metastases, especially in inhibiting osteoclast - mediated bone resorption.

Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases